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Introduction
A pivotal arm of innate immunity, the complement system is comprised of proteins present in both plasma and cell membranes that work in concert to mediate immune responses against invading pathogens and altered host cells, while at the same time shielding healthy host cells from destruction [1, 2] . The coordination of the complement system is induced through three pathways known as alternative, classical, and lectin. The alternative pathway is constitutively activated in plasma through the so-called tick-over mechanism of complement protein C3, while the latter two pathways, classical and lectin, are initiated on microbes or apoptotic/necrotic cells by their respective pattern recognition molecules [3] . Similar to alternative pathway, the classical pathway can also be induced in the fluid phase through the spontaneous intramolecular activation of complement complex C1 [4] . Central points of convergence for all three pathways of complement activation and propagation are complement proteins C3 and C5, whose cleavage fragments C3a/C3b and C5a/C5b, respectively, results in inflammatory responses, opsonophagocytosis, and formation of the membrane attack complex (MAC/C5b-9 n ) [5, 6] . The fragments C3a and C5a are anaphylatoxins that mediate activation of immune cells, such as macrophages and T cells, while C3b is an opsonin that tags foreign or altered cells for recognition and elimination by phagocytes [5, 6] . Lastly, the MAC complex penetrates lipid bilayers and induces lysis through osmotic effects [7] . Propagation of complement activation occurs through cleavage of C3 or C5 by convertases, which are complexes of cleavage products of C3, C4, and proteases Factor B (FB) and C2 [8] [9] [10] [11] .
The complexity of the complement system comes from the number of proteins and their networks of interactions involved in all three pathways. However, recent mathematical models targeting complement pathways have been developed to aid our understanding in the dynamics involved in mediating immune response through activation and regulation of complement species [12] [13] [14] [15] . To further these efforts, we previously developed a comprehensive model of the alternative pathway divided into four modules: (i) initiation (fluid phase); (ii) amplification (surfaces); (iii) termination (pathogen); and (iv) regulation (host cell and fluid phase) [16] . Based on these four modules we generated a system of 107 ordinary differential equations (ODEs) and 74 kinetic parameters. Here we present an updated and refined alternative pathway model of the complement system that takes into account dimerization states of complement fragments C3b and C4b, additional C3 and C5 convertases, IgG interactions with the C3b, and regulation of anaphylatoxins C3a and C5a. Relative to our first model [16] , this new model also contains fluid phase activation and propagation of the classical pathway, owed to the spontaneous autoactivation of C1. With these additions, our updated and refined model is now composed of 290 ordinary differential equations and 142 kinetic parameters.
The cascade of reactions "innate" to the complement system is equally supplemented with interactions that protect healthy host cells from destruction, under homeostasis. Recent studies highlight a number of diseases that are associated with under-regulation/over-activation of the alternative pathway due to mutations that target regulators (e.g. Factor H, FH) or propagators (convertases) of the alternative pathway [17] [18] [19] [20] [21] [22] . Diseases such as such as atypical hemolytic uremic syndrome (aHUS), age related macular degeneration (AMD), C3 glomerulonephritis (C3GN), and dense-deposit disease (DDD) are associated with overly active alternative pathway [18] [19] [20] [21] [23] [24] [25] [26] [27] . To better understand the dynamics of these disorders at the complement level, we have developed a generic disease state by targeting the most potent complement regulator FH. This regulator is chosen because alternative pathway-mediated disorders, mentioned above, implicate FH dysfunctionality, owed to altered effective concentrations or mutations that impair regulatory capabilities. In addition to modeling the disease state, we have also added to two therapy states by incorporating complement inhibitors, compstatin, targeting C3 [28] [29] [30] [31] [32] , and eculizumab, targeting C5 [33] [34] [35] , and compared their relative effects on regulating an overactivated complement system under FH regulatory impairment. Furthermore, we implemented different doses of compstatin and eculizumab to investigate their relative roles on mediating early and late stage complement biomarkers. In summary, we have generated four states of alternative and classical pathways with time profiles describing concentration levels of biomarkers C3, C3a-desArg, C5, C5a-desArg, FB and its fragments Ba and Bb, and fC5b-9 (a general term for fluid phase MAC/C5b-9) that are associated with alternative pathway dysregulation.
Methods

Mathematical model
Our mathematical model is based on the biochemical reactions shown in Fig 1. The biochemical reactions are generated from critical reading of papers with experimental and clinical data, published in the scientific literature. Using the cascade of biochemical reactions in the classical and alternative pathway, we generated a system of 290 ODEs with 142 kinetic parameters.
Similar to our previous model [16] , we organized the biochemical reactions and equations into modules that describe complement system: (i) initiation, Eqs S1-S55 of the Supplementary [32] .
Perturbation that leads to regulatory disorder is modeled by reducing FH concentration and kinetics by an order of magnitude as shown in Tables S1 and S2 (Tables S1 and S2 of Supplementary Material), and multi-parametric sensitivity analysis (MPSA) for global sensitivity are described in our previous paper [16] . Briefly, for MPSA we first selected kinetic parameters involved in our biochemical reactions of alternative and classical pathways. Then we generated ranges for each parameter to be large enough to cover all feasible variations. For each parameter set, we calculated the sum of squared errors between the observed and perturbed system output values. We used the results of this calculation to determine if the chosen set of parameters is acceptable or unacceptable. The cumulative frequency was calculated for both acceptable and unacceptable cases and was used to evaluate the sensitivity of each parameter using Kolmogorov-Smirnov statistic. Parameter ranges used in multi-parametric sensitivity analysis can be found in Table S3 be the same. This assumption is consistent with similar biochemical interaction between FH and serine protease, Bb, that is present on both convertases (C3(H 2 O)Bb, C3bBb). Lastly, due to the lack of kinetic data on the decay rates induced by complement regulators such as decayaccelerating factor (DAF), complement receptor 1 (CR1), and C4b-binding protein (C4BP), we assumed they will also have the same decay accelerating rate as FH because these regulators function in a FH-like manner by either inhibiting or deactivating C3/C5 convertases.
Biochemical Model
Below, we will describe the complement system pathways of Fig 1. These pathways entail activation, propagation, and regulation of the complement system. The pathways describe interactions of complement proteins, fragments, and complexes that operate entirely in the fluid phase, as well as those that bind to cell surfaces, undergoing further processing, and returning products to fluid phase. The characteristics of the surface of a red blood cell are used in the model [16] .
Initiation (fluid phase)
The alternative pathway is spontaneously activated in plasma through a process known as the tick-over reaction, and involves the spontaneous hydrolysis of an internal thioester bond in C3. [5] , nfC3b has an exposed highly-reactive internal thioester bond that is capable of indiscriminately binding to different surfaces via covalent attachment, or forming fluid phase C3b (fC3b) by interacting with water [37] [38] [39] . The fC3b fragment cannot covalently attach to cells but can still propagate the alternative pathway by associating with FB and following the same cascade of reactions as C3(H 2 O), forming form the fluid C3/C5 convertase, C3bBb [36, 40] .
Similar to the alternative pathway, the classical pathway also initiates in the fluid phase through the spontaneous autoactivation of component complex C1 [4] . This leads to the formation of activated C1 (denoted C1*) that cleaves C4. This process leads to the formation of C4a and nascent fluid phase C4b (nfC4b). Similar to nfC3b, nascent fluid C4b can covalently attach to nearby surface or form fluid phase C4b (fC4b) by interacting with water [41] . Complement C2 then interacts with C4b to form the proconvertase of the classical pathway, C4bC2. Similar to C4, this complex is also activated by C1* to form the C3/C5 convertase, C4bC2a.
In addition to the covalent bonds formed between nfC3b/nfC4b to cell membranes, covalent linkage can occur between C3b and C4b fragments, forming C3bC4b, C3bC3b, or C4bC4b complexes. These complexes can associate with FB or C2 to form C3/C5 convertases, fC4bC3bBb, fC3bC3bBb, fC3bC4bC2a, and fC4bC4bC2a [9] [10] [11] . Furthermore, C3b dimers, C3bC3b, can also covalently attach with immunoglobulin G, IgG, to form IgGC3bC3b [8] . This complex functions as a C3 convertase that cleaves C3 into C3a and nfC3b.
Amplification
Once nfC3b attaches covalently to a host surface, a cascade of reactions ensues where FB is recruited first, followed by FD cleavage to yield the surface bound C3/C5 convertase, C3bBb.
Since this enzyme is rather unstable, the only positive regulator of the alternative pathway, known as properdin, binds and extend the half-life of C3bBb by 10-fold [42, 43] . Similar to the propagation step in the fluid phase, formation of dimers associated with C3b or C4b occurs on the surface of host cells. These dimers, C3bC3b/C3bC4b, can associate with either FB, followed by activation step with FD to form the C3/C5 convertases (C3bC3bBb/C4bC3bBb). However, unlike C3bC3b/C3bC4b dimers in the fluid phase that can also bind to C2, the surface activation mechanism for C1* is not added since it requires antigens to anchor to the surface first [44] [45] [46] .
Here, host cells are under normal conditions while the impairment in our model only applies to FH in the fluid phase. Lastly, C3b dimers can also associate with properdin to form stabilized C3/C5 convertase that enhances complement activation within the vicinity of this convertase.
Termination
Cleavage of complement C5 by C3/C5 convertases such as fC3bBb or fC4bC2a, leads to the formation of C5a and C5b. Like C3a, C5a is a mediator of inflammation [5] . C5b binds to C6 and subsequently to C7 and forms C5b-7. This complex can insert itself into the lipid bilayer but also can form inactive micelles in the absence of cell membranes [47, 48] . Furthermore, C5b-7 binds to C8, followed by C9 to form fluid phase MACs (fC5b-9). However, if C5b-7 attaches to a cell, C8 binding occurs, followed by the attachments of multiple C9 molecules to from a MAC.
Presence of MACs compromise the integrity of cell membranes and induce cell death. In addition to fC3bBb/fC4bC2a cleaving C5, dimerized forms such as fC4bC3bBb or fC3bC4bC2a
can also cleave C5 but C5b remains loosely bound to the convertase while C5a is released in the fluid phase. When C5b is still bound to the convertase, it is capable of binding to C6.
Complement C7 then binds and subsequently leads to C5b-7 complex dissociating from the C3/C5 convertase.
Regulation
Multiple check-points are in place to ensure proper regulation of the complement system. FH and C4b (by C4BP) to suppress the propagation step. Inactivation of C3b is mediated through its cleavage to inactivated C3b (iC3b) by Factor I (FI) in conjunction with either FH, FHL-1, or CR1 as cofactors, while C4b is deactivated into C4d by FI with C4BP as its cofactor. Further cleavage of iC3b to C3dg is mediated by FI, using CR1 as a cofactor [1, 2] . In addition, other membrane bound regulators such DAF can also act in concert with FH, FHL-1, and C4BP to accelerate the decay of C3/C5 convertases [1, 2] . Furthermore, membrane cofactor protein (MCP)
is another cell-bound regulator that acts as a cofactor to deactivate C3b/C4b in conjunction with FI. Since MCP is not expressed on erythrocytes, it was not included in the model. Finally, late stage complement propagation in the terminal cascade is tightly controlled through fluid phase regulators such as Vitronectin (Vn) or Clusterin (Cn) that act on fC5b-7, while surface bound regulator CD59 inhibits C9 polymerization [7, 49] .
FH disorder, with compstatin and eculizumab treatments
Disorders of the alternative pathway, such as C3GN, DDD, AMD, and aHUS all implicate FH impairment through either reduced concentration (type 1 mutation) or binding/regulatory functionality (type 2 mutation) [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . To mimic clinical observations, we generated an FH disorder model by reducing its concentration and association rate constant by one order of magnitude (Tables S1 and S2 of Supplementary Material). After modeling FH disorder, we subsequently generated complement therapeutic states by incorporating into the FH disorder state known complement inhibitors, such as a compstatin family peptide and the monoclonal antibody eculizumab. Compstatin is small peptide that targets complement C3 and inhibits the cleavage of C3 by C3/C5 convertases , [28] [29] [30] . Similar in functionality to compstatin, eculizumab targets complement C5 and inhibits the cleavage of C5 by C3/C5 convertases [33] [34] [35] .
Dose dependence for compstatin and eculizumab
In the initial calculations, the concentrations of compstatin and eculizumab were taken to be 20fold higher than the concentrations of their respective targets, C3 and C5 (S1 Concentrations of compstatin and eculizumab were taken to be one-to-one and 5-fold lower than the concentrations of their respective targets. In total, in the dose-dependent study of compstatin we used concentrations: 1.4×10 -4 M (20-fold higher than C3), 7.1×10 -6 M (1-to-1 to C3) and
1.4×10 -6 M (5-fold lower than C3). In the dose-dependent study of eculizumab we used concentrations: 7.4×10 -6 M (20-fold higher than C5), 3.7×10 -7 M (1-to-1 to C5) and 7.4×10 -8 M (5fold lower than C5).
Results
Dynamics of complement activation, propagation, regulation, and inhibition
Our study presents the time profiles of the concentrations of complement components for biochemical reactions involved in the alternative and classical pathway of the complement system under four conditions: (i) normal state, corresponding to homeostasis in a healthy person, (ii) FH disorder state, corresponding to alternative pathway dysregulation owed to FH impairment, (iii) FH disorder state with compstatin treatment, and (iv) FH disorder state with eculizumab treatment.
C3 and its cleavage fragment, C3a-desArg, as biomarkers for FH disorder state
We first generated time profiles for the complement system's key substrate, C3, and its deactivated anaphylatoxin, C3a-desArg, as shown in Figs 2A and 2B. C3 under normal condition has a slow rate of consumption in which C3 levels reach a concentration of 6.6×10 -6 M within the first 25 minutes from a starting concentration of 7.1×10 -6 M (Fig 2A) . This change corresponds to a 7% decrease in blood plasma C3 within 25 minutes. cascade through the classical pathway is seen for the key interactions that affect levels of C5 ( Fig   6B) . This includes the activation step of C5 through the k cat of C3bC4bC2a, dissociation rate constant of C3bC4bC2a, and the regulatory steps of C4BP with fC4b and C3/C5 convertase (C4bC2a). Lastly, key interactions of the alternative pathway that affect the levels of C3 and C5
Sensitivity analysis
involve the inactivation step of C3b in complex with FH (C3bH). This complex is targeted by FI to form iC3b. Figures 6A and 6B show that inactivation of C3b in C3bH by the action of FI is an important step in mediating the levels of C3 and C5.
Dose dependence analysis for compstatin and eculizumab in modulating FH disorder state
Our results thus far have shown that using compstatin and eculizumab with a concentration of 20-fold higher than the concentration of their respective targets, C3 and C5, to be more than Fig 7A) , and 1.4×10 -6 M (5-fold lower than C3; Fig 7B) , for comparison to Fig 2B (compstatin concentrations of 1 .4×10 -4 M, 20fold higher than C3). The same fold-change in concentration was used for eculizumab: 3.7×10 -7 M (one-to-one to C5; Fig 7A) , and 7.4×10 -8 M (5-fold lower than C5; Fig 7B) , for comparison to Fig 2B (eculizumab concentration of 7 .4×10 -6 M, 20-fold higher than C5). The results show that the effect of one-to-one compstatin-C3 concentration nearly recovers the C3a-desArg concentration-time profile to that of normal state (Fig 7A) , whereas 5-fold lower compstatin concentration than C3 concentration is insufficient to regulate ( Fig 7B) . On the other hand, the effect of 20-fold higher compstatin concentration than C3 concentration is over-regulating (or over-restorative), keeping the C3a-desArg levels lower than those of the normal state ( Fig 2B) .
Lastly, variations in eculizumab have minor effects on regulating early complement fragment
C3a-desArg ( Figs 7A and B) .
After examining the effects of varying the concentrations of compstatin and eculizumab on C3a-desArg, we next investigated the effects of these inhibitors on late stage biomarker fC5b-9 ( Fig   8) . We used the same variations in concentrations for compstatin and eculizumab as used for C3a-desArg, described above. Different doses of compstatin had small effect and never recovered the fC5b-9 concentration-time profile to that of the normal state ( Figs 5 and 8) . In contrast, one-to-one eculizumab-C5 concentration nearly recovers the fC5b-9 concentration-time profile to that of normal state (Fig 8A) , whereas 5-fold lower eculizumab concentration than C5 concentration is insufficient to regulate ( Fig 8B) . As discussed above, the effect of 20-fold higher eculizumab concentration than C5 concentration is over-regulating (or over-restorative), keeping the fC5b-9 levels lower than those of the normal state ( Fig 5) .
Discussion
Modeling of fluid phase alternative and classical pathway activation, and relation to FHbased diseases
In the present study, we used mathematical modeling of the complement system to understand the complex interplay between complement activation/propagation and regulation. First, differential equations were used to model the biochemical reactions involved in the alternative and classical pathways of the complement system under normal condition (physiological condition in homeostasis). Second, we modeled an alternative pathway disordered state by impairing FH to better understand the dynamics of complement pathology in FH-mediated diseases, called herein FH disorder state. This negative regulator, FH, was chosen because alternative pathway-associated disorders, such as AMD, aHUS, C3GN, DDD, implicate FH impairment at the levels of lower effective concentration or altered binding kinetic parameters leading to improper regulation. Third, we added two complement therapeutic states by incorporating FH disorder state with compstatin treatment (targeting C3) and FH disorder state with eculizumab treatment (targeting C5). And lastly, using these four computational states, we generated concentration-time profiles for biomarkers associated with alternative pathway dysregulation, such as C3, C3a-desArg, C5, C5a-desArg, FB, Ba, Bb, and fC5b-9.
Biomarkers under normal state
Our results show only 7% consumption of C3 (Fig 2A) and <1% consumption of C5 ( Fig 3A) relative Fig 4B) and Bb (after convertase dissociation by FH, FHL, and CR1, or self-dissociation; Fig 4C) , are also produced in small amounts. Subsequently, proper regulation of convertases also leads to proper modulation of the cleavage rates of C3 and C5. This results in lower amounts of C3 being converted to nC3b and C3a (further deactivated to C3a-desArg), and C5 into C5b and C5a (further deactivated to C5a-desArg). Our model shows these events where the production of biomarkers C3a-desArg ( Fig   2B) and C5a-desArg ( Fig 3B) are produced in low amounts under normal conditions. However, C3a-desArg is shown to be at a higher concentration than C5a-desArg. And lastly, a termination step of the complement system is instigated by C5b associating with C6, C7, C8, and C9 to form fluid phase MAC/fC5b-9. Since the conversion of C5 into C5b and C5a is properly modulated, small amounts of fC5b-9 are produced as a result in the normal state ( Fig 5) .
Comparison of normal and FH disorder states
Introduction of alternative pathway dysregulation, through FH impairment, referred herein as FH disorder state, significantly reduced C3 levels by 76% relative to C3 blood plasma concentration (Fig 2A) . This means that suboptimal FH function results in increased levels and stability of alternative pathway C3/C5 convertases. These enzymes rapidly consume blood plasma C3 to produce elevated levels of C3a-desArg (after C3a deactivation; Fig 2B) and Altogether these data show that impairing FH has the effect of compromising the regulatory checkpoints to generate an overly active complement system with reduced levels of C3 and C5, coupled with elevated levels of inflammation markers C3a-desArg and C5a-desArg.
Effect of compstatin on FH disorder state
Compstatin inhibits cleavage of C3 to C3a and nC3b, and thus inhibits C3 consumption. The rapid reduction of C3 concentration shown in Fig 2A is not due to consumption, but rather it is owed to C3 being in complex with compstatin to form compstatin:C3 complexes (not shown in Fig 2) . Compstatin has an over-restorative effect on C3a-desArg, meaning that it brings down the concentration of C3a-desArg in the FH disorder state by about three orders of magnitude, while C3a-desArg levels in the normal state are about one order of magnitude lower than the FH disorder state. In contrast, compstatin has an under-restorative effect on C5a-desArg, meaning that although it brings down the concentration of C5a-desArg in the FH disorder state, it is still about one order of magnitude higher than the C5a-desArg concentration under the normal state ( Fig 3B) .
In summary, an overly active complement system under compstatin treatment better modulates levels of C3a-desArg than C5a-desArg. This outcome is due to regulation induced by compstatin in the early phases of complement activation to generate lower amounts of C3a, later becoming deactivated to form C3a-desArg. Although there is a compensatory effect, it is not clear what is the net effect of compstatin inhibition on C3a-/C5a-induced inflammatory response, given that C5a is a more potent pro-inflammatory protein than C3a. It has been suggested that C3a has both proinflammatory and anti-inflammatory properties [50] , whereas C5a is proinflammatory.
Therefore, in certain pathologies, C3a and C5a may have opposite roles, and this should be taken into account when selecting treatment drugs.
Furthermore, treatment with compstatin generates a trend for fC5b-9 that is similar to C5a-desArg but smaller in concentration magnitude ( Fig 5) . This is because the formation of fC5b-9
is based on the other C5 cleavage product, C5b, which is equivalent in concentration to C5a immediately after cleavage; however C5b is further involved in biochemical reactions that include inactivation, propagation on host cells, and regulation in fluid and host cells (Fig 1) . 
In terms of FB and its cleavage fragments (Ba and
Effect of eculizumab on FH disorder state
Eculizumab has a minor effect on C3 and its cleavage fragments, C3a and nC3b (Fig 2) , and on FB and its cleavage fragments, Ba and Bb (Fig 4) . This is because eculizumab acts on C5, and inhibits cleavage of C5 to C5a and C5b, thus inhibiting C5 consumption. The dramatic reduction of C5 concentration shown in Fig 3A is not due to consumption, but rather because treatment with eculizumab generates eculizumab:C5 complexes (not shown in Fig 3) . Eculizumab overrestores the concentrations of C5a-desArg and fC5b-9 in the FH disorder state to about four and three, respectively, orders of magnitude lower than the C5a-desArg and fC5b-9 concentrations in the normal state.
These results suggest that eculizumab may be a better inhibitor than compstatin for diseases that are driven by excess MAC/C5b-9 formation. The potency of eculizumab as a terminal cascade inhibitor is shown on the levels C5a-desArg and fC5b-9 concentrations. However, even in the absence of compstatin and eculizumab, in the FH disorder state the change in C5 concentration is small compared with the change in C3 concentration, relative to their concentration changes in the normal state. Depending on the disease, a treatment with inhibition at the early stages of the complement pathway (e.g. C3), or a treatment at the late stages of complement pathway (e.g.
C5)
, or a dual treatment may be necessary. The model may be useful to select the point of inhibition, at C3, C5, or other (e.g. FB, FD, fC5b-9, etc), depending on the specific effect we aim to suppress, e.g. inflammation, opsonophagocytosis, MAC/C5b-9 formation.
Sensitivity analysis
Our sensitivity analysis showed the classical pathway fluid phase activation as a major cross activator of the alternative pathway ( Fig 6) under normal conditions. The alternative pathway is initiated through tick-over process with a first order kinetic rate constant of 4.5×10 -6 s -1 while the classical pathway is spontaneously activated much faster through C1 with a kinetic rate constant of 2.8×10 -3 s -1 [4, 51] . Activated C1 (C1*) cleaves C4, followed by C4bC2 to form the classical pathway C3/C5 convertase C4bC2a. This enzyme can initiate the alternative pathway by cleaving C3 before the tick-over forms the initial convertase of the alternative pathway, C3(H 2 O)Bb. Thus, having a faster activation rate makes C1 the critical step in forming enzymes that can activate and propagate the alternative pathway in the fluid phase. Figure 6A displays this notion where the kinetic parameter that regulates C1* by the action of C1-INH is the most sensitive parameter that mediates levels of C3. Lastly, while the remaining critical parameters of the classical pathway are involved in interactions that affect steps that either form or inhibit C3/C5 convertases of the classical pathway, the alternative pathway has a single key regulation step mediated by FH in conjunction with FI that controls the levels of C3 and C5 (Fig 6) . The potency of FH not only lies in accelerating the decay rate of convertases, but also working in concert with FI to cleave C3b into iC3b. This cleavage step reduces the rate of C3/C5 convertases formation since iC3b does not from convertases.
Effects of varying doses of compstatin and eculizumab on C3a-desArg and fC5b-9 in FH disorder state
Varying concentrations of compstatin affect levels of C3a-desArg in a dose-dependent manner, while different doses of eculizumab showed minor effects on C3a-desArg ( Figs 2B and 7) .
Unlike eculizumab, treatment with compstatin generate compstatin:C3 complexes that are shielded from cleavage by C3/C5 convertases. This step inhibits early cascade of reactions induced by nC3b and C3a that later form C3/C5 convertases and C3a-desArg, respectively.
However, reducing the levels of compstatin further compromises regulation and increase the levels of C3a-desArg. For instance, restorative capabilities of compstatin are significantly impaired when the concentration of compstatin is 5-fold lower than that of C3. Under this concentration, compstatin has an under-restorative effect by generating C3a-desArg levels that are closer to the FH disorder state than the normal state.
Although production of the early-stage complement biomarker C3a-desArg is highly dependent on compstatin and not eculizumab, late-stage complement fC5b-9 is more dependent on eculizumab than compstatin (Figs 5 and 8 ). Varying the doses of compstatin generated fC5b-9 levels that were closer to fC5b-9 levels under the FH disorder state. However, treatment with eculizumab generates a dose-dependent response of fC5b-9 levels because of the eculizumab:C5
complexes that are formed. This eculizumab:C5 complex is protected from cleavage by convertases to C5a/C5b fragments, and thus C5b-based initiation of the cascade of reactions that lead to fC5b-9 formation is inhibited. As the levels of eculizumab increase, less fC5b-9
complexes are formed. Comparison of the results of Figs 5 and 8 show this relation where fC5b-9 levels are the lowest under the highest eculizumab concentration (20-fold higher than the concentration of C5). Conversely, highest levels of fC5b-9 are generated under the lowest eculizumab concentration (5-fold lower than the concentration of C5).
In summary, compstatin shows higher restorative efficacy for early-stage biomarker C3a-desArg, whereas eculizumab has higher restorative efficacy for late-stage biomarker fC5b-9. Also, oneto-one drug-to-target protein concentrations are sufficient for complete restoration of the FH disorder state to the normal state in this model. However, we should point out that this concentration ratio may change when we incorporate in the model drug metabolism and complement protein turnover steps.
Relation of the model to clinical disorders and therapeutics
Altogether our data highlight the importance of FH in regulating the levels of the central substrate of the complement system, C3. Furthermore, the presence of unimpaired FH is also essential for regulating the levels of blood plasma FB. Disorders related to the alternative pathway, such as C3GN, DDD, and aHUS are typically characterized with low levels of plasma C3 and FB, while FB cleavage products, Ba and Bb, are elevated [23] [24] [25] [26] [27] . Although these disorders are also associated with mutations/polymorphisms in other complement protein, such as C3, FI, FB, and FH related proteins, in addition to FH mutations/polymorphisms, our data shows that just impairing FH is sufficient to generate clinically observed trends for C3, FB, Ba, and Bb. In support of this notion, biomarker profiling of patients with C3GN and DDD shows that having type 1 mutation in FH (reduced levels of FH concentration) was sufficient to generate to low levels of plasma C3 and FB [27] . Furthermore, absence of plasma FH has also been observed to cause C3 glomerulopathies in humans [27] . Thus, FH plays a pivotal role in ensuring proper regulation, and mutations that alter concentration or kinetics of FH will instigate the dysregulation of the alternative pathway.
In addition to generating biomarker trends associated with the alternative pathway dysregulation, our computational model also shows treatment with eculizumab effectively regulates terminal complement activity while having a minor effect on early complement activity induced by C3.
This coupled effect was observed for paroxysmal nocturnal hemoglobinuria (PNH) patients where treatment with eculizumab regulated terminal complement activation but some patients still suffered from extravascular opsonophagocytosis (also referred to as extravascular hemolysis) that is attributed to early phase complement activation and propagation induced by C3 [52] . Subsequently, a recent study showed that complement intervention by compstatin protected PNH erythrocytes from complement mediated lysis and modulated early phase complement deposition and propagation induced by C3 [53] . These findings are consistent with our computational model where eculizumab shows little effect on C3 level under FH impairment, whereas compstatin regulates potently early-stage complement activity and less potently latestage complement activation. However, our model also shows eculizumab is much more potent regulator of late-stage complement activation and propagation than compstatin. Thus, efficient complement therapy may require disease-specific biomarker targeting, or dual point targeting.
Overall, this study serves as a proof-of-concept on the capabilities of the model in predicting the dynamics of the complement system under homeostasis and disease states, and in predicting the effects of drugs in restoring the complement system from a disease state to the normal state.
Conclusion
We have generated a comprehensive model of the alternative and classical pathway of the disorder is about one order of magnitude higher than normal. Compstatin treatment generates lower levels of fC5b-9 than FH disorder state, but fC5b-9 levels are still higher compared to normal state. Finally, eculizumab treatment shows production of fC5b-9 to be about three orders of magnitude lower than normal. 
